A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
About this clinical trial
The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis. Participants will take one tablet daily of either zasocitinib or a matching placebo, along with one capsule daily of either over-encapsulated deucravacitinib or a matching placebo, for a duration of 16 weeks. Participants will be in the study for up to 25 weeks, which includes screening period of up to 35 days, a 16-week treatment period, and a 4-week safety follow-up period.

At a glance
What medical conditions are being studied?
What is the clinical trial testing?
Zasocitinib, Deucravacitinib, Placebo to match zasocitinib, Placebo to match deucravacitinib
How many participants are being enrolled?
600
Are placebos part of the clinical trial?
Yes
When is the clinical trial being conducted?
Jul 2025 - Jul 2026
How long is participation in the clinical trial?
Participants will be in the study for about 25 weeks.
Key requirements
Sexes
All
Age
18+ Years
Healthy volunteers?
No